Insilico Medicine to Unveil Four AI-Generated Oncology Programs at AACR 2026 Annual Meeting in San Diego

Insilico Medicine showcases four novel oncology programs discovered via generative AI at AACR 2026, demonstrating accelerated drug development timelines.

By: AXL Media

Published: Apr 1, 2026, 11:28 AM EDT

Source: Information for this report was sourced from InSilico Medicine

Generative AI Integration in Oncology Drug Discovery

The integration of generative artificial intelligence and automation is fundamentally altering the trajectory of oncology research by streamlining the identification of novel therapeutic targets. Insilico Medicine, recently listed on the Hong Kong Stock Exchange, utilizes its end-to-end Pharma.AI platform to bridge the gap between generative biology and de novo molecular design. By processing trillions of data points, the system identifies biological vulnerabilities in cancer cells and engineers molecular fragments to inhibit them. This methodology has allowed the company to nominate 20 preclinical candidates since 2021, requiring the synthesis of significantly fewer molecules than traditional pharmaceutical R&D processes.

Selective Pan-KRAS Inhibition for Solid Tumors

One of the primary highlights at the upcoming AACR meeting is ISM6166, an oral pan-KRAS inhibitor designed to address the high prevalence of KRAS alterations in solid tumors. While existing selective inhibitors often target specific mutations like KRAS G12C, they frequently face challenges with drug resistance. ISM6166 aims to overcome these limitations by targeting all major KRAS variants in both active and inactive states. Crucially, the molecule is engineered to spare HRAS and NRAS, which are essential for normal cellular function, thereby potentially reducing the toxicity risks associated with broader RAS family inhibition.

Restoring Immunity via Cbl-b Checkpoint Inhibition

In the field of cancer immunotherapy, Insilico is introducing ISM3830, a small molecule generated by AI to target the Cbl-b intracellular immune checkpoint. Unlike traditional checkpoints located on the cell surface, Cbl-b operates internally to negatively regulate the activation of T cells and Natural Killer (NK) cells. By inhibiting this protein, ISM3830 has demonstrated the ability to restore the function of suppressed immune cells and increase their infiltration into tumors. This approach offers a distinct mechanism for enhancing the body’s innate and adaptive immune responses against solid malignancies.